BioWorld

Feb. 25, 2003

VaxGen's AIDS Vaccine Comes Up Short; Blacks, Asians Show Benefit

VaxGen Inc. did not receive the results it and so many others hoped for after releasing Phase III trial data for its experimental AIDS vaccine, resulting in an investment backlash against the company's stock. (BioWorld Today) Read More

Trimeris, Roche Implement Program In Europe, Set Price

Monocyte Cells, Easily Accessible To Draw From Blood, Can Double For Dicey Embryonic Stem Cells

Peregrine Gets FDA OK For Cotara Phase III, Awaits Partner

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...